Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 36, Issue 8, 2018, Pages 773-779

  Overman, Michael J ^a   Lonardi, Sara ^b   Wong, Ka Yeung Mark ^e   Lenz, Heinz Josef ^g   Gelsomino, Fabio ^c   Aglietta, Massimo ^d   Morse, Michael A ^h   Van Cutsem, Eric ⁱ   McDermott, Ray ^m   Hill, Andrew ^f   Sawyer, Michael B ⁿ   Hendlisz, Alain ^j   Neyns, Bart ^k   Svrcek, Magali ^o   Moss, Rebecca A ^l   Ledeine, Jean Marie ^l   Cao, Z Alexander ^l   Kamble, Shital ^l   Kopetz, Scott ^a   André, Thierry ^o  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Tasman Oncology Research Ltd   (Australia)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j JULES BORDET INSTITUTE   (Belgium)

^k UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^l BRISTOL MYERS SQUIBB   (United States)

^m ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL OUTCOME; COHORT ANALYSIS; COLITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RASH; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; AGED; COLORECTAL TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; IPILIMUMAB; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM METASTASIS; NIVOLUMAB; SURVIVAL RATE;

EID: 85043396361     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.76.9901     Document Type: Article

References (33)

1. National Cancer Institute: Surveillance, Epidemiology, and End Results Program: Cancer stat facts: Colon and rectum cancer. https://seer.cancer.gov/statfacts/html/colorect.html
2. International Agency for Research on Cancer: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in2012-Cancer fact sheets. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
3. Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-413, 2017
4. Koopman M, Kortman GA, Mekenkamp L, et al: Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100:266-273, 2009
5. Venderbosch S, Nagtegaal ID, Maughan TS, et al: Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20:5322-5330, 2014
6. Innocenti F, Ou F, Zemla T, et al: Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (alliance). J Clin Oncol 35, 2017 (suppl; abstr 3504)
7. Stintzing S, Wirapati P, Lenz H, et al: Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. J Clin Oncol 35, 2017 (suppl; abstr 3510)
8. Tougeron D, Cohen R, Sueur B, et al: A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. Ann Oncol 28, 2017 (suppl 5; abstr 533P)
9. Lenz H, Ou F, Venook AP, et al: Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (alliance). J Clin Oncol 35, 2017 (suppl; abstr 3511)
10. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
11. Overman MJ, McDermott R, Leach JL, et al: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 18:1182-1191, 2017
12. Diaz LA, Marabelle A, Delord J, et al: Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol 35, 2017 (suppl; abstr 3071)
13. Diaz LA, Marabelle A, Kim TW, et al: Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann Oncol 28, 2017 (suppl 5; abstr 386P)
14. Sepulveda AR, Hamilton SR, Allegra CJ, et al: Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:1453-1486, 2017
15. Van Cutsem E, Cervantes A, Adam R, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386-1422, 2016
16. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Colon cancer-Version 2.2017. https://www.nccn.org/professionals/physician-gls/pdf/colon.pdf
17. Opdivo (nivolumab): US prescribing information. Bristol-Myers Squibb, Princeton, NJ, 2017
18. Yervoy (ipilimumab): US prescribing information. Bristol-Myers Squibb, Princeton, NJ, 2017
19. Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4combination blockadeexpands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanomatumors. Proc Natl Acad Sci USA 107:4275-4280, 2010
20. Antonia SJ, López-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883-895, 2016
21. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
22. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
23. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
24. US Department of Health and Human Services, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
25. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
26. EuroQol Group: EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 16:199-208, 1990
27. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
28. Pickard AS, Neary MP, Cella D: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5:70, 2007
29. Bell ML, Fairclough DL: Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Stat Methods Med Res 23:440-459, 2014
30. Le DT, Uram JN, Wang H, et al: Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol 34, 2016 (suppl; abstr 103)
31. Keytruda (pembrolizumab): US prescribing information. Merck, Whitehouse Station, NJ, 2017
32. Janjigian YY, Ott PA, Calvo E, et al: Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. J Clin Oncol 35, 2017 (suppl; abstr 4014)
33. Overman MJ, Kopetz S, Lonardi S, et al: Nivolumab ± ipilimumab treatment (tx) efficacy, safety, and biomarkers in patients (pts) withmetastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): Results fromthe CheckMate-142 study. Ann Oncol 27, 2016 (suppl 6; abstr 149)